Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS
暂无分享，去创建一个
L. Kappos | C. Polman | S. Galetta | M. Hutchinson | B. Weinstock-Guttman | E. Havrdová | G. Giovannoni | C. Hotermans | P. O'Connor | W. Stuart | J. Phillips | F. Lynn | Paul W. O’Connor